TLR3 and inflammatory bowel disease: These results suggest that the priming of MSCs through TLR3 stimulation and IFN-γ is a promising new strategy to increase the therapeutic efficacy of MSC on IBD and might be able to solve the problems that the current MSC therapies are facing.